Immunotherapy/chemotherapy study shows promise at ASCO 2020

June 4, 2020 By Melissa Soria

A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results.  The study enrolled 55 patients and showed a median survival of 20.1 months. Of those 55 patients, 31 demonstrated a partial response, and 22 had stable disease. Most frequently observed adverse events included fatigue, nausea, anemia, and constipation…

2019 ASCO Interview with Dr. Nicholas Vogelzang

June 7, 2019 By swarren

Each year, the American Society of Clinical Oncology unites oncologists from all over the country at the organization’s annual meeting. This year, we spoke with leading oncologist Dr. Nicholas Vogelzang and his son, our Lead Counsel Nicholas Vogelzang, about this year’s theme: Caring for every patient; learning from every patient. As a law firm that…